Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085332
Status:
COMPLETED
Last Update Posted:
2014-01-13
First Post:
2004-06-10
Brief Title:
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma Cancer
Sponsor:
Gynecologic Oncology Group
Organization:
GOG Foundation
Study Overview
Official Title:
A Phase II Evaluation of Weekly Docetaxel NSC 628503 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma cancer
PURPOSE This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma cancer
Detailed Description:
OBJECTIVES
Determine the antitumor activity of docetaxel in patients with recurrent or persistent endometrial carcinoma
Determine the toxicity of this drug in these patients
OUTLINE This is a multicenter study
Patients receive docetaxel IV over 1 hour on days 1 8 and 15 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 19-51 patients will be accrued for this study within 10-18 months
Determine the antitumor activity of docetaxel in patients with recurrent or persistent endometrial carcinoma
Determine the toxicity of this drug in these patients
OUTLINE This is a multicenter study
Patients receive docetaxel IV over 1 hour on days 1 8 and 15 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
PROJECTED ACCRUAL A total of 19-51 patients will be accrued for this study within 10-18 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000368634 | None | None | None |